APA (7th ed.) Citation

L, R., M, L., M, N., TC, H., AD, S., & RL, D. (2022). The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. Journal of immunotherapy (Hagerstown, Md. : 1997), 45(8), 335. https://doi.org/10.1097/CJI.0000000000000427

Chicago Style (17th ed.) Citation

L, Robillard, Liao M, Nguyen M, Harding TC, Simmons AD, and Dusek RL. "The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models." Journal of Immunotherapy (Hagerstown, Md. : 1997) 45, no. 8 (2022): 335. https://doi.org/10.1097/CJI.0000000000000427.

MLA (9th ed.) Citation

L, Robillard, et al. "The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models." Journal of Immunotherapy (Hagerstown, Md. : 1997), vol. 45, no. 8, 2022, p. 335, https://doi.org/10.1097/CJI.0000000000000427.